ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Calliditas Therapeutics AB

Calliditas Therapeutics AB (CALT)

40.0001
0.00
( 0.00% )
Updated: 18:00:00

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
40.0001
Bid
20.29
Ask
60.85
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
40.0001
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CALT Latest News

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm PR Newswire STOCKHOLM, Sept. 16, 2024 STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas...

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB...

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...

Calliditas Interim Report January to June 2024

Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...

Calliditas Interim Report January to June 2024

Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...

Invitation to the presentation of Calliditas´s interim report January - June 2024

Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...

Invitation to the presentation of Calliditas´s interim report January - June 2024

Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

CALT - Frequently Asked Questions (FAQ)

What is the current Calliditas Therapeutics AB share price?
The current share price of Calliditas Therapeutics AB is US$ 40.0001
What is the 1 year trading range for Calliditas Therapeutics AB share price?
Calliditas Therapeutics AB has traded in the range of US$ 0.00 to US$ 0.00 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ONCBeiGene Ltd
 184.62
(733.50%)
37.96k
RAINRain Enhancement Technologies Holdco Inc
 5.75
(375.21%)
120.46k
NITON2OFF Inc
US$ 0.968
(290.32%)
402.21M
CTCXCarmell Corporation
US$ 0.7923
(183.88%)
264.11M
SPCBSuperCom Ltd
US$ 9.2899
(92.74%)
30.71M
NMRANeumora Therapeutics Inc
US$ 2.0283
(-80.87%)
26.29M
THCHTH International Limited
US$ 0.71
(-80.00%)
32.1k
SISIShineco Inc
US$ 2.12
(-53.20%)
1.03M
BDMDBaird Medical Investment Holdings Ltd
US$ 4.68
(-38.42%)
3.15M
SIDUSidus Space Inc
US$ 3.26
(-33.47%)
8.42M
NITON2OFF Inc
US$ 0.9637
(288.59%)
402.24M
CTCXCarmell Corporation
US$ 0.7925
(183.95%)
264.11M
CGBSCrown LNG Holdings Ltd
US$ 0.6902
(72.51%)
254.13M
SVMHSRIVARU Holding Ltd
US$ 0.0495
(17.58%)
150.44M
XTIAXTI Aerospace Inc
US$ 0.04195
(-2.44%)
149.78M

CALT Discussion

View Posts
tw0122 tw0122 7 months ago
$CALT $38 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.

The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9 months was associated with estimated glomerular filtration rate (eGFR) benefit compared with continuous treatment with sparsentan.

Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids (SGC), such as Prednisone and Prednisolone.

"It was wonderful to participate in ERA 2024 and present data contributing to the discussion on the need for effective treatments in IgAN," said Richard Philipson, Chief Medical Officer of Calliditas, " We continue to gather evidence that highlights the importance of treating the underlying autoimmune pathogenesis associated with IgAN, and we believe TARPEYO, as the only approved immunomodulating therapy designed to target the production of Gd-IgA1, has the potential to become a cornerstone therapy in IgAN."

Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting.

Presentation Analyses:

Title: "Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan"

A matching-adjusted indirect comparison (MAIC) methodology is a widely accepted and relevant methodology for comparing treatments across trials in the absence of head-to-head comparisons. Here the effects of Nefecon, marketed as TARPEYO® and sparsentan, marketed as FILSPARI™, on kidney function deterioration in patients with IgAN were compared, as assessed by eGFR change from baseline at 9, 12 and 24 months. Results from the MAIC showed significantly favorable effects of Nefecon versus sparsentan on eGFR across all time points analyzed. Mean differences in the absolute change in eGFR of 5.68mL/min/1.73 m2 (95% credible interval [Crl] 3.14, 8.20; p
👍️0
Monksdream Monksdream 9 months ago
CALT over $20
👍️0

Your Recent History

Delayed Upgrade Clock